| Abstrakt: |
A recent study conducted by researchers at the Mario Negri Institute for Pharmacological Research in Milan, Italy, has found that the BRCA1 foci test may be a predictive biomarker for the response to olaparib in ovarian cancer patient-derived xenograft models. The study focused on high-grade ovarian carcinoma, which is typically treated with surgery followed by platinum-based chemotherapy and poly-ADP ribose polymerase inhibitors (PARPis). The researchers found that a low BRCA1 foci score was associated with a positive response to olaparib and cisplatin, while a high score indicated resistance to therapy. This study suggests that the BRCA1 foci test could potentially be used to identify HRD ovarian carcinomas and predict response to olaparib. [Extracted from the article] |
